These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2646301)

  • 1. Intravenous human rabies immunoglobulin for post-exposure prophylaxis: serum rabies neutralizing antibody concentrations and side-effects.
    Aoki FY; Rubin ME; Friesen AD; Bowman JM; Saunders JR
    J Biol Stand; 1989 Jan; 17(1):91-104. PubMed ID: 2646301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies.
    Lang J; Gravenstein S; Briggs D; Miller B; Froeschle J; Dukes C; Le Mener V; Lutsch C
    Biologicals; 1998 Mar; 26(1):7-15. PubMed ID: 9637744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a Novel Human Rabies Monoclonal Antibody to Human Rabies Immunoglobulin for Postexposure Prophylaxis: A Phase 2/3, Randomized, Single-Blind, Noninferiority, Controlled Study.
    Gogtay NJ; Munshi R; Ashwath Narayana DH; Mahendra BJ; Kshirsagar V; Gunale B; Moore S; Cheslock P; Thaker S; Deshpande S; Karande S; Kumbhar D; Ravish HS; Harish BR; Pisal SS; Dhere R; Parulekar V; Blackwelder WC; Molrine DC; Kulkarni PS
    Clin Infect Dis; 2018 Jan; 66(3):387-395. PubMed ID: 29020321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rabies neutralizing antibody in serum of children compared to adults following post-exposure prophylaxis.
    Aoki FY; Rubin ME; Fast MV
    Biologicals; 1992 Dec; 20(4):283-7. PubMed ID: 1305405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adults.
    Kerdpanich P; Chanthavanich P; De Los Reyes MR; Lim J; Yu D; Ama MC; Mojares Z; Casula D; Arora AK; Pellegrini M
    PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006340. PubMed ID: 29874228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody responses to human diploid cell vaccine for rabies with and without human rabies immune globulin.
    Mertz GJ; Nelson KE; Vithayasai V; Makornkawkeyoon S; Rosanoff EI; Tint H; Wiktor TJ
    J Infect Dis; 1982 May; 145(5):720-7. PubMed ID: 7077095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human rabies prevention--United States, 2008: recommendations of the Advisory Committee on Immunization Practices.
    Manning SE; Rupprecht CE; Fishbein D; Hanlon CA; Lumlertdacha B; Guerra M; Meltzer MI; Dhankhar P; Vaidya SA; Jenkins SR; Sun B; Hull HF;
    MMWR Recomm Rep; 2008 May; 57(RR-3):1-28. PubMed ID: 18496505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An economical regimen of human diploid cell strain anti-rabies vaccine for post-exposure prophylaxis.
    Warrell MJ; Warrell DA; Suntharasamai P; Viravan C; Sinhaseni A; Udomsakdi D; Phanfung R; Xueref C; Vincent-Falquet JC; Nicholson KG; Bunnag D; Harinasuta T
    Lancet; 1983 Aug; 2(8345):301-4. PubMed ID: 6135830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies with human diploid cell strain rabies vaccine and human antirabies immunoglobulin in man.
    Nicholson KG; Turner GS
    Dev Biol Stand; 1978; 40():115-20. PubMed ID: 680384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy results of simulated post-exposure prophylaxis with human immune globulin (HRIG; KEDRAB) co-administered with active vaccine in healthy subjects: a comparative phase 2/3 trial.
    Matson MA; Schenker E; Stein M; Zamfirova V; Nguyen HB; Bergman GE
    Hum Vaccin Immunother; 2020; 16(2):452-459. PubMed ID: 31549899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis.
    Wongsaroj P; Udomchaisakul P; Tepsumethanon S; Khawplod P; Tantawichien T
    Vaccine; 2013 Mar; 31(13):1748-51. PubMed ID: 23370149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of rabies vaccine with human rabies immunoglobulin and reliability of a 2-1-1 schedule application for postexposure treatment.
    Vodopija I; Sureau P; Smerdel S; Lafon M; Baklaić Z; Ljubicić M; Svjetlicić M
    Vaccine; 1988 Jun; 6(3):283-6. PubMed ID: 3420976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. MAS054 Clinical Investigator Group.
    Lang J; Simanjuntak GH; Soerjosembodo S; Koesharyono C
    Bull World Health Organ; 1998; 76(5):491-5. PubMed ID: 9868840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time of administration of rabies immunoglobulins and adequacy of antibody response upon post-exposure prophylaxis: a descriptive retrospective study in Belgium.
    Soentjens P; Croughs M; Burm C; Declerq S; Clerinx J; Maniewski U; Van Den Broucke S; Theunissen C; Huits R; Brosius I; Florence E; Kenyon C; Van Griensven J; Van Ierssel S; Lynen L; Balliauw K; Van Gucht S; Van Esbroeck M; Vlieghe E; Bottieau E; Van Herrewege Y
    Acta Clin Belg; 2021 Apr; 76(2):91-97. PubMed ID: 31483218
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunogenicity, safety and lot consistency in adults of a chromatographically purified Vero-cell rabies vaccine: a randomized, double-blind trial with human diploid cell rabies vaccine.
    Jones RL; Froeschle JE; Atmar RL; Matthews JS; Sanders R; Pardalos J; Moeller L; Chin JE; Famula M; Briggs DJ; Lang J
    Vaccine; 2001 Sep; 19(32):4635-43. PubMed ID: 11535311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simplified and economical intradermal regimen of purified chick embryo cell rabies vaccine for postexposure prophylaxis.
    Suntharasamai P; Chaiprasithikul P; Wasi C; Supanaranond W; Auewarakul P; Chanthavanich P; Supapochana A; Areeraksa S; Chittamas S; Jittapalapongsa S
    Vaccine; 1994 May; 12(6):508-12. PubMed ID: 8036824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of reducing rabies immunoglobulin dosage for passive immunization against rabies: results of In vitro and In vivo studies.
    Madhusudana SN; Ashwin BY; Sudarshan S
    Hum Vaccin Immunother; 2013 Sep; 9(9):1914-7. PubMed ID: 23792347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody response to suckling mouse brain rabies vaccines for post exposure treatment.
    Chanthavanich P; Suntharasamai P; Warrell MJ; Viravan C; Looareesuwan S; Supanaranond W; Karbwang J; Warrell DA; Phillips RE; Sinhaseni A
    Trans R Soc Trop Med Hyg; 1987; 81(2):260-3. PubMed ID: 3617187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity.
    Bakker AB; Python C; Kissling CJ; Pandya P; Marissen WE; Brink MF; Lagerwerf F; Worst S; van Corven E; Kostense S; Hartmann K; Weverling GJ; Uytdehaag F; Herzog C; Briggs DJ; Rupprecht CE; Grimaldi R; Goudsmit J
    Vaccine; 2008 Nov; 26(47):5922-7. PubMed ID: 18804136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of immunogenicity, reactogenecity and safety of purified chick embryo cell rabies vaccine and neural tissue rabies vaccine.
    Deshpande AK; Londhe VA; Akarte S; Briggs D
    J Assoc Physicians India; 2003 Jul; 51():655-8. PubMed ID: 14621031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.